Bromfenac 0.09% for the Treatment of Macular Edema Secondary to Noninfectious Uveitis.

Purpose: The topical nonsteroidal anti-inflammatory drug bromfenac 0.09% has a potential benefit in uveitic macular edema (UME) with a safe side effect profile. The aim of the study is to assess the efficacy of bromfenac sodium solution in the treatment of UME.

Methods: The charts of 10 patients with macular edema due to noninfectious uveitis treated with bromfenac 0.09% were reviewed retrospectively. The main outcomes studied were the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT) compared 4 months before bromfenac initiation, at the time of its initiation, and 4 months later.

Results: Twelve eyes of 10 patients were included. BCVA and CRT were unchanged 4 months befoew bromfenac compared to the time of bromfenac initiation ( = 1.0 and = 0.2, respectively). There were a significant improvement in BCVA after 4 months of bromfenac treatment ( = 0.043) and a significant decrease in CRT ( = 0.002). Subretinal fluid resolved completely in 8/9 eyes, and 4/9 eyes had a complete resolution of cystoid macular edema at 4 months.

Conclusion: Bromfenac may be a useful addition to the treatment of UME.